I2 is an inhibitor of the oxidoreductase ERO1A (IC50 = 8.1 µM), a mediator of the unfolded protein response (UPR).1 Under cancer-related hypoxia conditions, ERO1A favors the folding of the angiogenic protein VEGFA leading to cancer cell growth and spread. I2 inhibited the metabolic activity of DMA-MB-231 triple negative breast cancer cells and impaired migration and VEGF secretion. Tumors in C57/BL6Jmice showed decreased levels of VEGF and PD-L1 when treated with I2.
* VAT and and shipping costs not included. Errors and price changes excepted
